期刊
SCIENCE ADVANCES
卷 7, 期 1, 页码 -出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciadv.abc2100
关键词
-
资金
- Intramural Research Program of the NIH, National Cancer Institute
- Center for Cancer Research
- Common Fund of the Office of the Director of the NIH
- NCI
- NHGRI
- NHLBI
- NIDA
- NIMH
- NINDS
- NCI-UMD Partnership for Integrative Cancer Research fellowship
This study investigates the role of synthetic lethality in cancer risk, finding that the extent of co-inactivation of cancer synthetic lethal (cSL) gene pairs in normal tissues is associated with lower and delayed cancer risk. The up-regulation of more cSL gene pairs in cells exposed to carcinogens and in premalignant stages suggests a potential role of synthetic lethality in tumorigenesis. Moreover, the tissue specificity of tumor suppressor genes is linked to the expression of their cSL partner genes in normal tissues.
Various characteristics of cancers exhibit tissue specificity, including lifetime cancer risk, onset age, and cancer driver genes. Previously, the large variation in cancer risk across human tissues was found to strongly correlate with the number of stem cell divisions and abnormal DNA methylation levels. Here, we study the role of synthetic lethality in cancer risk. Analyzing normal tissue transcriptomics data in the Genotype-Tissue Expression project, we quantify the extent of co-inactivation of cancer synthetic lethal (cSL) gene pairs and find that normal tissues with more down-regulated cSL gene pairs have lower and delayed cancer risk. Consistently, more cSL gene pairs become up-regulated in cells treated by carcinogens and throughout premalignant stages in vivo. We also show that the tissue specificity of numerous tumor suppressor genes is associated with the expression of their cSL partner genes across normal tissues. Overall, our findings support the possible role of synthetic lethality in tumorigenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据